Portal de Periódicos da CAPES

Pharmacokinetics of cysteamine bitartrate following gastrointestinal infusion

2006; Wiley; Volume: 63; Issue: 1 Linguagem: Inglês

10.1111/j.1365-2125.2006.02734.x

1365-2125

Meredith C. Fidler, Bruce A. Barshop, Jon A. Gangoiti, Reena Deutsch, Michael Martin, Jerry A. Schneider, Ranjan Dohil,

Methemoglobinemia and Tumor Lysis Syndrome

Aims Although cysteamine was first used in the treatment of cystinosis in 1976 and approved by the FDA as cysteamine bitartrate (Cystagon™) in 1994, surprisingly little pharmacological data are available for this compound. Cysteamine and its related drugs are currently being evaluated for the treatment of Huntington’s and Parkinson’s disease. The aim of te study was to understand the pharmacokinetics of cysteamine bitartrate following gastrointestinal infusion. Method Cysteamine bitartrate was delivered through a naso‐enteric catheter into the stomach ( n = 8), small intestine ( n = 8) and caecum ( n = 4) of normal subjects. Plasma cysteamine concentrations were determined using LC‐MS/MS. Results The rate and extent of drug absorption were assessed by comparing AUC(0, ∞), C max and t max , among the gastrointestinal infusion sites. Total cysteamine exposure, expressed as area under the curve (AUC(0, ∞)) was greatest when the drug was infused into the small intestine (4331.3 ± 1907.6 min × µ m ) followed by stomach (3901.9 ± 1591.9 min × µ m ) and caecum (3141.4 ± 1627.6 min × µ m ). Cysteamine infusion into the small intestine resulted in the most rapid rise to maximal plasma concentrations ( t max = 21 ± 0.56 min); t max was delayed to 50 ± 26 min and 64 ± 26 min after gastric and caecal infusion, respectively. The maximum cysteamine plasma concentration ( C max ) was reached after infusion of the drug into the small intestine (51 ± 21 µ m ), which was higher than plasma C max concentrations after gastric (39 ± 16 µ m ) and caecal infusion (23 ± 15 µ m ). Conclusions The pharmacokinetic data generated help extend our understanding of cysteamine.